Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 197Bevacizumab 163Fluorouracil 155Capecitabine 137Gemcitabine 133Leucovorin 112pembrolizumab 100Cisplatin 94Drug Therapy 89Irinotecan 81Radiotherapy 73sintilimab 70durvalumab 65Paclitaxel 64130-nm albumin-bound paclitaxel 64Specimen Handling 62Cetuximab 61lenvatinib 60tislelizumab 58Nivolumab 56Magnetic Resonance Spectroscopy 55Folfox protocol 55Blood Specimen Collection 52atezolizumab 48Biopsy 46Surgical Procedures, Operative 40Immune Checkpoint Inhibitors 38Taxes 37Albumin-Bound Paclitaxel 37HMPL-013 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hyperthermia, Induced × Gastrointestinal × Clear all
NCT07062055 2026-05-08

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
54 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡